To determine the mechanism of symptom relief with treatment by botulinum toxin injection in persons with adductor spasmodic dysphonia (ADSD), we evaluated the effects of unilateral thyroarytenoid muscle injections on both injected and noninjected muscles in 10 subjects with ADSD, using electromyography on both sides of the larynx before and after treatment. The subjects' speech symptoms were reduced (p = .005) 2 weeks following injection, when the electromyographic study occurred. Muscle activation levels and the numbers of spasmodic muscle bursts decreased significantly (p ≤ .03) postinjection in both the injected and noninjected muscles. The reductions in laryngeal muscle bursts correlated with symptom reduction (r ≥ .7) in all muscles. Reductions in laryngeal muscle bursts did not relate to either absolute or normalized levels of muscle activity before or after botulinum toxin injection. The results suggest that changes in the central pathophysiology are responsible for changes in speech symptoms following treatment.
BlitzerABrinMFFahnSLovelaceRE. Clinical and laboratory characteristics of focal laryngeal dystonia: study of 110 cases. Laryngoscope1988; 98: 636–40.
2.
BlitzerALovelaceREBrinMFFahnSFinkME. Electromyographic findings in focal laryngeal dystonia (spastic dysphonia). Ann Otol Rhinol Laryngol1985; 94: 591–4.
3.
BlitzerABrinMF. Laryngeal dystonia: a series with botulinum toxin therapy. Ann Otol Rhinol Laryngol1991; 100: 85–9.
4.
ShippTIzdebskiKReedCMorrisseyP. Intrinsic laryngeal muscle activity in a spastic dysphonic patient. J Speech Hear Disord1985; 50: 54–9.
5.
NashEALudlowCL. Laryngeal muscle activity during speech breaks in adductor spasmodic dysphonia. Laryngoscope1996; 106: 484–9.
6.
LudlowCL. Treatment of speech and voice disorders with botulinum toxin. JAMA1990; 264: 2671–5.
7.
JankovicJBrinMF. Therapeutic uses of botulinum toxin. N Engl J Med1991; 324: 1186–94.
8.
LudlowCLBagleyJAYinSGKodaJ. A comparison of different injection techniques in the treatment of spasmodic dysphonia with botulinum toxin. J Voice1992; 6: 380–6.
9.
ZwirnerPMurryTWoodsonGE. A comparison of bilateral and unilateral botulinum toxin treatments for spasmodic dysphonia. Eur Arch Otorhinolaryngol1993; 250: 271–6.
10.
AdamsSGHuntEJCharlesDALangAE. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results. J Otolaryngol1993; 22: 171–5.
11.
LudlowCLRhewKNashEA. Botulinum toxin injection for adductor spasmodic dysphonia. In: JankovicJHallettM, eds. Therapy with botulinum toxin. New York, NY: Marcel Dekker, 1994: 437–50.
12.
AldersonKHoldsJBAndersonRL. Botulinum-induced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm. Neurology1991; 41: 1800–5.
13.
BorodicGEFerrantRJPearceLBAldersonK. Pharmacology and histology of the therapeutic application of botulinum toxin. In: JankovicJHallettM, eds. Therapy with botulinum toxin. New York, NY: Marcel Dekker, 1994: 119–57.
14.
HarrisCPAldersonKNebekerJHoldsJBAndersonRL. Histologic features of human orbicularis oculi treated with botulinum A toxin. Arch Ophthalmol1991; 109: 393–5.
15.
HoldsJBAldersonKFoggSGAndersonRL. Motor nerve sprouting in human orbicularis muscle after botulinum A injection. Invest Ophthalmol Vis Sci1990; 31: 964–7.
16.
LudlowCL. Pathophysiology of the spasmodic dysphonias. In: Bell-BertiFRaphaelLJ, eds. Producing speech: contemporary issues for Katherine Safford Harris. Woodbury, NY: American Institute of Physics, 1995: 291–308.
17.
BlitzerABrinMFFahnSLovelaceRE. Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia). Laryngoscope1988; 98: 193–7.
18.
LudlowCLHallettMSedorySEFujitaMNauntonRF. The pathophysiology of spasmodic dysphonia and its modification by botulinum toxin. In: BerardelliABeneckeRManfrediMMarsdenCD, eds. Motor disturbances. 2nd ed. Orlando, Fla: Academic Press, 1990: 274–88.
19.
ShaariCMGeorgeEWuBLBillerHFSandersI. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope1991; 101: 960–4.
20.
GeorgeEFZimblerMWuB-LBillerHFSandersI. Quantitative mapping of the effect of botulinum toxin injections in the thyroarytenoid muscle. Ann Otol Rhinol Laryngol1992; 101: 888–92.
21.
LangDJBrinMFWarnerCLFahnSLovelaceRE. Distant effects of local injection of botulinum toxin. Muscle Nerve1987; 10: 552–5.
22.
LudlowCLSchulzGM. Physiological changes following treatment of speech and voice disorders with botulinum toxin. In: DasGuptaBR, ed. Botulinum and tetanus neurotoxins: neurotransmission and biomedical aspects. New York, NY: Plenum Press, 1992: 594–608.
23.
GelbDJYoshimuraDMOlneyRKLowensteinDHAminoffMJ. Change in pattern of muscle activity following botulinum toxin injections for torticollis. Ann Neurol1991; 29: 370–6.
24.
PastorAMMoreno-LopezBDe la CruzRRDelgado-GarciaJM. Effects of botulinum neurotoxin type A on abducens motoneurons in the cat: ultrastructural and synaptic alterations. Neuroscience1997; 81: 457–78.
25.
Moreno-LopezBDe la CruzRRPastorAMDelgado-GarciaJM. Effects of botulinum neurotoxin type A on abducens motoneurons in the cat: alterations of the discharge pattern. Neuroscience1997; 81: 437–55.
26.
FilippiGMErricoPSantarelliRBagoliniBManniE. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol (Stockh) 1993; 113: 400–4.
27.
KirchnerJAWykeBD. Articular reflex mechanisms in the larynx. Ann Otol Rhinol Laryngol1965; 74: 749–68.
28.
KirchnerJAWykeBD. The innervation of the laryngeal joints in cat. J Anat1964; 98: 684.
DedoHH. Recurrent laryngeal nerve section for spastic dysphonia. Ann Otol Rhinol Laryngol1976; 85: 451–9.
31.
BorodicGEFerranteRPearceLBSmithK. Histologic assessment of dose-related diffusion and muscle-fiber response after therapeutic botulinum A toxin injections. Mov Disord1994; 9: 31–9.
32.
CastellanosPFGatesGAEsselmanGSongFVannierMWKuoM. Anatomic considerations in botulinum toxin type A therapy for spasmodic dysphonia. Laryngoscope1994; 104: 656–62.
33.
Van PeltFLudlowCLSmithPJ. Comparison of muscle activation patterns in adductor and abductor spasmodic dysphonia. Ann Otol Rhinol Laryngol1994; 103: 192–200.
34.
LoebGEGansC. Electromyography for experimentalists. Chicago, Ill: The University of Chicago, 1986.
35.
WatsonBCSchaeferSDFreemanFJDembowskiJKondraskeGRoarkR. Laryngeal electromyographic activity in adductor and abductor spasmodic dysphonia. J Speech Hear Res1991; 34: 473–82.
36.
InagiKFordCNBlessDMHeiseyD. Analysis of factors affecting botulinum toxin results in spasmodic dysphonia. J Voice1996; 10: 306–13.
37.
KeeneMF Lucas. Muscle spindles in the human laryngeal muscles. J Anat1961; 95: 25–9.
38.
SuzukiMKirchnerJA. Sensory fibers in the recurrent laryngeal nerve. An electrophysiological study of some laryngeal afferent fibers in the recurrent laryngeal nerve of the cat. Ann Otol Rhinol Laryngol1969; 78: 21–31.
